Home · Health · Nov 14 archive

Endocrinologists Discuss Type 2 Diabetes Remission and Management

Confirmed

Health Desk

In Short: Endocrinologists discuss the possibility of Type 2 diabetes remission within 90 days and the importance of ongoing monitoring.

According to Dr. Kellis, the likelihood of achieving remission decreases significantly for those who have had Type 2 diabetes for eight to ten years.

Dr. Himika Chawla, a senior consultant at PSRI Hospital, elaborates on the possibility of Type 2 diabetes remission within 90 days and the lifestyle changes that can help manage blood sugar levels.

YouTube — Aveniq Official YouTube

Israeli researchers have developed a treatment that can restore normal blood sugar levels in about 30 percent of mice with Latent Autoimmune Diabetes in Adults (LADA), a condition that accounts for 9.1% of all diabetes cases worldwide.

A study published in Signal Transduction and Targeted Therapy suggests that Type 2 diabetes is characterized by a progressive loss of islet β cell insulin secretion, usually occurring after insulin resistance.

Researchers from the Medical University of South Carolina are developing a stem cell therapy to restore insulin-producing beta cells in people with type 1 diabetes without requiring immunosuppressive drugs.

A study published in Diabetes Research and Clinical Practice maps the unique challenges faced by older patients using continuous glucose monitoring (CGM) and helps clinicians anticipate potential roadblocks.

What this adds

The possibility of Type 2 diabetes remission within 90 days is discussed, emphasizing the importance of ongoing monitoring and lifestyle changes.

The study on LADA in mice and the stem cell therapy for type 1 diabetes add to the ongoing research in diabetes management and treatment.

Background

Eledon Pharmaceuticals' experimental immune therapy, tegoprubart, has shown promise in helping some patients with type 1 diabetes (T1D) stop using insulin, according to a study published by Healthcare Brew.

Eledon Pharmaceuticals' experimental immune therapy, tegoprubart, has shown promise in helping some patients with type 1 diabetes (T1D) stop using insulin, according to a study published by Healthcare Brew.

What's confirmed

What's still developing

Sources